ESC Issues First Comprehensive Cardiomyopathy Guidelines The European Society of Cardiology has released new guidelines for cardiomyopathies, their first major comprehensive international guidelines to address diagnosis and treatment of the broad causes of heart muscle dysfunction.

AHA/ACC Issue Updated Chronic Coronary Disease Guidelines The latest clinical practice guideline for managing patients with chronic coronary disease (CCD) takes an evidence-based and patient-centered approach to care and includes key updates on revascularization, beta-blocker use, and routine functional and anatomic testing. Developed by the American Heart Association (AHA), the American College of Cardiology (ACC), and other specialty societies, the 2023 guideline both updates and consolidates ACC/AHA guidelines previously published in 2012 and 2014 for the management of patients with stable ischemic heart disease.

Russian national congress of cardiology 2019

FDA Clears Architect Stat High-Sensitivity Troponin Test for MI The US Food and Drug Administration (FDA) has approved the Architect Stat (Abbott Laboratories) high-sensitivity troponin-I assay, which can detect myocardial infarction (MI) faster and more accurately than other troponin tests, according to the company.

World Heart Day 2019 This year on World Heart Day, as part of our mission to ensure heart health equity for all, we want to create a global community of Heart Heroes … people from all walks of life who are acting now to live longer, better, heart-healthy lives by making a promise: for MY HEART, for YOUR HEART, for ALL OUR HEARTS.

ESC 2019: Wrap up in Russian - Live and interactive programme In collaboration with the Russian Society of Cardiology, this programme is designed to present a selection of scientific highlights from ESC Congress and discuss clinical practice implications with experts.

ESC Congress 2019 together with World Congress of Cardiology ESC Congress 2019 together with World Congress of Cardiology Saturday 31 August - Wednesday 4 September 2019 Paris - France

Announcement of the European Congress of Cardiology From August 31 to September 4, 2019, he Congress of the European Society of Cardiology in conjunction with the World Congress of Cardiology - will be held in Paris (France).

Trial Evaluating Sacubitril/Valsartan for HFpEF Misses Primary End Point Full detailed data from PARAGON-HF will be presented at the ESC Congress 2019 in September. Novartis announced topline results from the phase 3 PARAGON-HF study evaluating the safety and efficacy of sacubitril/valsartan (Entresto) in heart failure patients with preserved ejection fraction (HFpEF).

ESC Congress 2019 together with World Congress of Cardiology Full detailed data from PARAGON-HF will be presented at the ESC Congress 2019 in September. Novartis announced topline results from the phase 3 PARAGON-HF study evaluating the safety and efficacy of sacubitril/valsartan (Entresto) in heart failure patients with preserved ejection fraction (HFpEF).